USD 0.64
(3.23%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 99.64 Million USD | 19.02% |
2022 | 83.72 Million USD | 467.56% |
2021 | 14.75 Million USD | -69.54% |
2020 | 48.42 Million USD | 79.88% |
2019 | 26.92 Million USD | 162.78% |
2018 | 10.24 Million USD | -91.89% |
2017 | 126.27 Million USD | -13.98% |
2016 | 146.79 Million USD | -22.23% |
2015 | 188.75 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 27.87 Million USD | 0.0% |
2024 Q1 | - USD | -100.0% |
2023 Q3 | - USD | -100.0% |
2023 Q1 | - USD | -100.0% |
2023 Q2 | 57.15 Million USD | 0.0% |
2023 Q4 | 99.64 Million USD | 0.0% |
2023 FY | 99.64 Million USD | 19.02% |
2022 Q4 | 83.72 Million USD | 0.0% |
2022 FY | 83.72 Million USD | 467.56% |
2022 Q2 | 101.93 Million USD | 0.0% |
2021 Q2 | 23.91 Million USD | 0.0% |
2021 FY | 14.75 Million USD | -69.54% |
2021 Q4 | 14.75 Million USD | 0.0% |
2020 FY | 48.42 Million USD | 79.88% |
2020 Q4 | 48.42 Million USD | 0.0% |
2020 Q2 | 40.9 Million USD | 0.0% |
2019 FY | 26.92 Million USD | 162.78% |
2019 Q2 | 38.12 Million USD | 0.0% |
2019 Q4 | 26.92 Million USD | 0.0% |
2018 FY | 10.24 Million USD | -91.89% |
2017 FY | 126.27 Million USD | -13.98% |
2016 FY | 146.79 Million USD | -22.23% |
2015 FY | 188.75 Million USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AstraZeneca PLC | 28.58 Billion USD | 99.651% |
Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.76% |
Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -135.742% |
Novartis AG | 26.34 Billion USD | 99.622% |
PT Kalbe Farma Tbk. | 40.4 Million USD | -146.613% |